Joshua Jennings
Stock Analyst at TD Cowen
(3.38)
# 1,001
Out of 4,732 analysts
68
Total ratings
46.03%
Success rate
5.15%
Average return
Main Sectors:
Stocks Rated by Joshua Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVR Anteris Technologies Global | Initiates: Buy | $15 | $5.99 | +150.42% | 1 | Jan 7, 2025 | |
| PODD Insulet | Maintains: Buy | $264 → $324 | $275.81 | +17.47% | 1 | Jan 3, 2025 | |
| BSX Boston Scientific | Maintains: Buy | $100 → $110 | $98.66 | +11.49% | 7 | Dec 12, 2024 | |
| CBLL CeriBell | Maintains: Buy | $31 → $36 | $21.04 | +71.10% | 2 | Dec 9, 2024 | |
| TMDX TransMedics Group | Maintains: Buy | $175 → $120 | $57.20 | +109.79% | 9 | Nov 18, 2024 | |
| HUMA Humacyte | Reiterates: Buy | $10 | $4.41 | +126.76% | 2 | Oct 18, 2024 | |
| ALUR Allurion Technologies | Initiates: Buy | $50 | $2.93 | +1,606.48% | 1 | Oct 2, 2024 | |
| PRCT PROCEPT BioRobotics | Maintains: Buy | $75 → $99 | $76.02 | +30.23% | 3 | Sep 16, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Hold | $143 → $119 | $109.56 | +8.62% | 1 | Sep 6, 2024 | |
| VCEL Vericel | Maintains: Buy | $55 → $60 | $59.07 | +1.57% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $83 → $80 | $75.09 | +6.54% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $3 | $0.79 | +279.75% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $100 → $70 | $69.78 | +0.32% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $195 → $185 | $147.03 | +25.82% | 1 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 | $30.98 | +29.12% | 4 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $365 → $400 | $383.42 | +4.32% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $34.56 | +73.61% | 4 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $34 | $35.15 | -3.27% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $18 | $7.35 | +144.90% | 3 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $114 → $125 | $84.38 | +48.14% | 1 | Feb 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $25 | $17.64 | +41.72% | 1 | Dec 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 | $113.48 | +14.56% | 9 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $5 | $2.08 | +140.38% | 1 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $117 | $88.08 | +32.83% | 3 | May 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $450 | $15.85 | +2,739.12% | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $12 | $11.57 | +3.72% | 1 | Sep 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $306 → $275 | $237.38 | +15.85% | 1 | Feb 7, 2020 |
Anteris Technologies Global
Jan 7, 2025
Initiates: Buy
Price Target: $15
Current: $5.99
Upside: +150.42%
Insulet
Jan 3, 2025
Maintains: Buy
Price Target: $264 → $324
Current: $275.81
Upside: +17.47%
Boston Scientific
Dec 12, 2024
Maintains: Buy
Price Target: $100 → $110
Current: $98.66
Upside: +11.49%
CeriBell
Dec 9, 2024
Maintains: Buy
Price Target: $31 → $36
Current: $21.04
Upside: +71.10%
TransMedics Group
Nov 18, 2024
Maintains: Buy
Price Target: $175 → $120
Current: $57.20
Upside: +109.79%
Humacyte
Oct 18, 2024
Reiterates: Buy
Price Target: $10
Current: $4.41
Upside: +126.76%
Allurion Technologies
Oct 2, 2024
Initiates: Buy
Price Target: $50
Current: $2.93
Upside: +1,606.48%
PROCEPT BioRobotics
Sep 16, 2024
Maintains: Buy
Price Target: $75 → $99
Current: $76.02
Upside: +30.23%
Zimmer Biomet Holdings
Sep 6, 2024
Maintains: Hold
Price Target: $143 → $119
Current: $109.56
Upside: +8.62%
Vericel
Aug 27, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $59.07
Upside: +1.57%
Aug 13, 2024
Maintains: Hold
Price Target: $83 → $80
Current: $75.09
Upside: +6.54%
Aug 8, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $0.79
Upside: +279.75%
Jul 25, 2024
Downgrades: Hold
Price Target: $100 → $70
Current: $69.78
Upside: +0.32%
Jul 18, 2024
Maintains: Buy
Price Target: $195 → $185
Current: $147.03
Upside: +25.82%
May 10, 2024
Downgrades: Hold
Price Target: $40
Current: $30.98
Upside: +29.12%
Apr 11, 2024
Maintains: Buy
Price Target: $365 → $400
Current: $383.42
Upside: +4.32%
Mar 12, 2024
Maintains: Outperform
Price Target: $50 → $60
Current: $34.56
Upside: +73.61%
Aug 4, 2023
Maintains: Outperform
Price Target: $52 → $34
Current: $35.15
Upside: -3.27%
May 11, 2023
Maintains: Outperform
Price Target: $14 → $18
Current: $7.35
Upside: +144.90%
Feb 10, 2023
Maintains: Outperform
Price Target: $114 → $125
Current: $84.38
Upside: +48.14%
Dec 30, 2022
Maintains: Outperform
Price Target: $6 → $25
Current: $17.64
Upside: +41.72%
Dec 13, 2022
Maintains: Outperform
Price Target: $130
Current: $113.48
Upside: +14.56%
Nov 11, 2022
Maintains: Outperform
Price Target: $7 → $5
Current: $2.08
Upside: +140.38%
May 27, 2022
Maintains: Outperform
Price Target: $125 → $117
Current: $88.08
Upside: +32.83%
Dec 7, 2021
Initiates: Outperform
Price Target: $450
Current: $15.85
Upside: +2,739.12%
Sep 3, 2020
Initiates: Outperform
Price Target: $12
Current: $11.57
Upside: +3.72%
Feb 7, 2020
Downgrades: Market Perform
Price Target: $306 → $275
Current: $237.38
Upside: +15.85%